Switching to Coformulated Rilpivirine (RPV), Emtricitabine (FTC) and Tenofovir Alafenamide from Either RPV, FTC and Tenofovir Disoproxil Fumarate (TDF) or Efavirenz, FTC and TDF: 96-week Results from Two Randomized Clinical Trials

Overview

Journal HIV Med

Publisher Wiley

Specialty Infectious Diseases

Date 2018 Aug 14

PMID 30101539

Citations 24

Authors

D Hagins

C Orkin

E S Daar

A Mills

C Brinson

E DeJesus

F A Post

J Morales-Ramirez

M Thompson

O Osiyemi

B Rashbaum

H-J Stellbrink

C Martorell

H Liu

Y-P Liu

D Porter

S E Collins

D Sengupta

M Das

Affiliations

Soon will be listed here.

Abstract

Objectives: The single-tablet regimen rilpivirine, emtricitabine and tenofovir alafenamide (RPV/FTC/TAF) for treatment of HIV-1-infected adults was approved based on bioequivalence. We assessed the clinical efficacy, safety and tolerability of switching to RPV/FTC/TAF from either RPV/FTC/tenofovir disoproxil fumarate (TDF) or efavirenz (EFV)/FTC/TDF.

Methods: We conducted two distinct randomized, double-blind, active-controlled, noninferiority trials in participants taking RPV/FTC/TDF (Study 1216) and EFV/FTC/TDF (Study 1160). Each study randomized virologically suppressed (HIV-1 RNA < 50 copies/mL) adults (1:1) to switch to RPV/FTC/TAF or continue their current regimen for 96 weeks. We evaluated efficacy as the proportion with HIV-1 RNA < 50 copies/mL using the Food and Drug Administration snapshot algorithm and prespecified bone and renal endpoints at week 96.

Results: We randomized and treated 630 participants in Study 1216 (RPV/FTC/TAF, n = 316; RPV/FTC/TDF, n = 314) and 875 in Study 1160 (RPV/FTC/TAF, n = 438; EFV/FTC/TDF, n = 437). In both studies, the efficacy of switching to RPV/FTC/TAF was noninferior to that of continuing baseline therapy at week 96, with respective percentages of patients with HIV RNA < 50 copies/mL being 89.2% versus 88.5% in Study 1216 [difference 0.7%; 95% confidence interval (CI) -4.3 to +5.8%] and 85.2% versus 85.1% in Study 1160 (difference 0%; 95% CI -4.8 to +4.8%). No participant on RPV/FTC/TAF developed treatment-emergent resistance versus two on EFV/FTC/TDF and one on RPV/FTC/TDF. Compared with continuing baseline therapy, significant improvements in bone mineral density and renal tubular markers were observed in the RPV/FTC/TAF groups (P < 0.001).

Conclusions: Switching to RPV/FTC/TAF from RPV/FTC/TDF or EFV/FTC/TDF was safe and effective and improved bone mineral density and renal biomarkers up to 96 weeks with no cases of treatment-emergent resistance.

Citing Articles

Metabolic Outcomes of Changing From Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine to Rilpivirine/Tenofovir Alafenamide/Emtricitabine: A Longitudinal Study.

Wu P, Lin H, Chen H, Huang P, Ke M Health Sci Rep. 2024; 7(12):e70275.

PMID: 39698519 PMC: 11653086. DOI: 10.1002/hsr2.70275.

Cardiometabolic health in people with HIV: expert consensus review.

Batterham R, Bedimo R, Diaz R, Guaraldi G, Lo J, Martinez E J Antimicrob Chemother. 2024; 79(6):1218-1233.

PMID: 38656584 PMC: 11144490. DOI: 10.1093/jac/dkae116.

Tenofovir amibufenamide tenofovir alafenamide for treating chronic hepatitis B: A real-world study.

Peng W, Jiang C, Yang F, Zhou N, Chen K, Liu J World J Gastroenterol. 2023; 29(44):5907-5918.

PMID: 38111506 PMC: 10725562. DOI: 10.3748/wjg.v29.i44.5907.

Broadening access to tenofovir alafenamide for the treatment and prevention of HIV-1 infection.

Osuala E, Naidoo A, Dooley K, Naidoo K, Perumal R Expert Rev Clin Pharmacol. 2023; 16(10):939-957.

PMID: 37612306 PMC: 10613124. DOI: 10.1080/17512433.2023.2251387.

Antivirals for prevention of hepatitis B virus mother-to-child transmission in human immunodeficiency virus positive pregnant women co-infected with hepatitis B virus.

Ugwu E, Eleje G, Ugwu A, Nwagha U, Ikechebelu J, Umeh U Cochrane Database Syst Rev. 2023; 6:CD013653.

PMID: 37306558 PMC: 10259198. DOI: 10.1002/14651858.CD013653.pub2.

References

Orkin C, DeJesus E, Ramgopal M, Crofoot G, Ruane P, LaMarca A . Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. Lancet HIV. 2017; 4(5):e195-e204. DOI: 10.1016/S2352-3018(17)30031-0. View

Ford N, Shubber Z, Pozniak A, Vitoria M, Doherty M, Kirby C . Comparative Safety and Neuropsychiatric Adverse Events Associated With Efavirenz Use in First-Line Antiretroviral Therapy: A Systematic Review and Meta-Analysis of Randomized Trials. J Acquir Immune Defic Syndr. 2015; 69(4):422-9. DOI: 10.1097/QAI.0000000000000606. View

Maggiolo F . Efavirenz: a decade of clinical experience in the treatment of HIV. J Antimicrob Chemother. 2009; 64(5):910-28. PMC: 2760464. DOI: 10.1093/jac/dkp334. View

Hall A, Hendry B, Nitsch D, Connolly J . Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis. 2011; 57(5):773-80. DOI: 10.1053/j.ajkd.2011.01.022. View

Goff Jr D, Lloyd-Jones D, Bennett G, Coady S, DAgostino R, Gibbons R . 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 129(25 Suppl 2):S49-73. DOI: 10.1161/01.cir.0000437741.48606.98. View

Sax P, Wohl D, Yin M, Post F, DeJesus E, Saag M . Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015; 385(9987):2606-15. DOI: 10.1016/S0140-6736(15)60616-X. View

Arribas J, Thompson M, Sax P, Haas B, McDonald C, Wohl D . Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results. J Acquir Immune Defic Syndr. 2017; 75(2):211-218. DOI: 10.1097/QAI.0000000000001350. View

Thamrongwonglert P, Chetchotisakd P, Anunnatsiri S, Mootsikapun P . Improvement of lipid profiles when switching from efavirenz to rilpivirine in HIV-infected patients with dyslipidemia. HIV Clin Trials. 2016; 17(1):12-6. DOI: 10.1080/15284336.2015.1112480. View

Raffi F, Orkin C, Clarke A, Slama L, Gallant J, Daar E . Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults. J Acquir Immune Defic Syndr. 2017; 75(2):226-231. PMC: 5427981. DOI: 10.1097/QAI.0000000000001344. View

10.

Tungsiripat M, Kitch D, Glesby M, Gupta S, Mellors J, Moran L . A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS. 2010; 24(11):1781-4. PMC: 2913151. DOI: 10.1097/QAD.0b013e32833ad8b4. View

11.

DeJesus E, Ramgopal M, Crofoot G, Ruane P, LaMarca A, Mills A . Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b,.... Lancet HIV. 2017; 4(5):e205-e213. DOI: 10.1016/S2352-3018(17)30032-2. View

12.

Cockcroft D, GAULT M . Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16(1):31-41. DOI: 10.1159/000180580. View

13.

Gutierrez F, Fulladosa X, Barril G, Domingo P . Renal tubular transporter-mediated interactions of HIV drugs: implications for patient management. AIDS Rev. 2014; 16(4):199-212. View

14.

Friis-Moller N, Ryom L, Smith C, Weber R, Reiss P, Dabis F . An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study. Eur J Prev Cardiol. 2015; 23(2):214-23. DOI: 10.1177/2047487315579291. View

15.

Santos J, Saumoy M, Curran A, Bravo I, Llibre J, Navarro J . The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial. Clin Infect Dis. 2015; 61(3):403-8. DOI: 10.1093/cid/civ296. View

16.

Behrens G, Maserati R, Rieger A, Domingo P, Abel F, Wang H . Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles. Antivir Ther. 2012; 17(6):1011-20. DOI: 10.3851/IMP2305. View

17.

Shubber Z, Calmy A, Andrieux-Meyer I, Vitoria M, Renaud-Thery F, Shaffer N . Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. AIDS. 2013; 27(9):1403-12. DOI: 10.1097/QAD.0b013e32835f1db0. View

18.

Lochet P, Peyriere H, Lotthe A, Mauboussin J, Delmas B, Reynes J . Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med. 2003; 4(1):62-6. DOI: 10.1046/j.1468-1293.2003.00136.x. View

19.

Mollan K, Smurzynski M, Eron J, Daar E, Campbell T, Sax P . Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med. 2014; 161(1):1-10. PMC: 4204642. DOI: 10.7326/M14-0293. View